From Insight to Action: Tackling the MASLD and MASH Epidemic-Module 2: Overcoming Diagnostic Inertia

Video Transcription

Video Summary

Dr. Raman Rajpal's webinar module addresses overcoming diagnostic inertia in MASLD/MASH within endocrinology. MASLD is highly prevalent, especially in type 2 diabetes patients (around 70%), with many progressing to MASH and fibrosis, yet underdiagnosed due to knowledge gaps, over-reliance on liver enzymes, and lack of standardized screening. Traditional diagnostics like liver enzymes and ultrasound miss many cases, whereas non-invasive tools such as the FIB-4 score and FibroScan provide better detection. The FIB-4 score is a simple, cost-effective tool also predicting cardiovascular risk. Diagnostic inertia also stems from systemic factors like absence of screening protocols, limited specialist access, and patient asymptomatic nature leading to low awareness. Solutions include implementing structured screening algorithms (e.g., ADA guidelines), multidisciplinary care models, patient education, EMR-based prompts, and promoting early detection. Early diagnosis and timely intervention can significantly reduce morbidity and mortality associated with MASLD/MASH, with endocrinologists playing a critical frontline role in recognizing and managing this silent but serious liver disease.

Meta Tag

Concept Fatty Liver Disease

Concept Metabolic Dysfunction-Associated Steatohepatitis

Concept Diagnostic Inertia

Concept FIB-4 Index

Concept Type 2 Diabetes

Keywords

MASLD

MASH

diagnostic inertia

FIB-4 score

FibroScan

endocrinology

Fatty Liver Disease

Metabolic Dysfunction-Associated Steatohepatitis

Diagnostic Inertia

FIB-4 Index

Type 2 Diabetes